Abstract
Aim: We aimed to explore the association between all-cause mortality and cardiovascular health (CVH) lifestyle interventions (as accurately quantified by Life’s essential 8) in prediabetic patients and to observe the dose-response relationship of the potential association.
Methods and Participants: The retrospective study included 5344 participants with prediabetes (age: 52.9 ±15.8 years; (51.6% of men)). The Life’s essential 8 (LE8) score includes four health indicators and four health behaviors. We calculated Cox proportional hazard ratios (HRS) for all-cause mortality in subgroups of high CVH (≥80), low CVH (≤50), and moderate CVH (50-79) based on the CVH quantification score of LE8, and explored the dose-response relationship of potential associations. We also performed separate analyses of the associations of all-cause mortality with each LE8 components and CVH health behaviors and indicators.
Results: In the median follow-up period of 8.33 years, 658 deaths occurred. Compared with participants with high CVH, the covariate-adjusted HR(95%CI) for participants with moderate and low CVH were 2.55(1.23-5.31) and 3.92 (1.70-9.02), respectively. There was a dose-response relationship between the improvement of CVH status and the reduction of all-cause mortality (P-overall < 0.0001, P-nonliner = 0.7989). The improvement of CVH health behaviors has a more significant protective effect on patients with prediabetes than CVH health indicators.
Conclusion: High CVH status, quantified by LE8, has a significant effect on preventing mortality outcomes in prediabetic adults in the U.S.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by research grants from the National Natural Science Foundation of China (Y.J., 82370818, Z.Z., 82270862); Natural Science Foundation of Guangdong Province(Y.J.,2024A1515012744); the Guangzhou Science and Technology Project (Y.J.,2024A04J5098); and the National Undergraduate Training Program for Innovation and Entrepreneurship, Southern Medical University (Z.Z., 202312121031, Y.J., S202312121167).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used (or will use) ONLY openly available human data that were originally located at:NCHS:https://www.cdc.gov/nchs/nhanes/index.htm
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced are available online at NCHS:https://www.cdc.gov/nchs/nhanes/index.htm
